|
|
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.
Number of employees : 910 people.
|
|
|
| 2018 | 2019 | Delta | | USD (in Million) | % | USD (in Million) | % | | Enterovirus 71 Vaccines | 162.54 | 70.8% | 149.22 | 60.6% | -8.19% | | Inactivated Hepatitis Vaccines | 63.43 | 27.6% | 57.95 | 23.6% | -8.63% | | Mumps Vaccines | 1.66 | 0.7% | 19.73 | 8% | +1089.39% | | Influenza Vaccines | 2.03 | 0.9% | 19.15 | 7.8% | +844.03% |
|
|
|
| 2018 | 2019 | Delta | | USD (in Million) | % | USD (in Million) | % | | China | 215.12 | 93.7% | 227.11 | 92.3% | +5.57% | | Foreign Countries | 14.53 | 6.3% | 18.94 | 7.7% | +30.36% |
|
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
| Stock A |
1 |
98,903,243 |
45,138,108 |
45.6% |
0 |
0.0% |
45.6% |
|
|
|
| Name | Equities | % | | 1Globe Capital LLC | 18,515,315 |
26.0% | | SAIF Advisors Ltd. | 10,780,820 |
15.2% | | Wei Dong Yin | 6,359,500 |
8.94% | | CDH Investment Advisory Pte. Ltd. | 6,000,000 |
8.43% | | Vivo Capital LLC | 5,900,000 |
8.29% | | Sansar Capital Management LLC | 2,953,503 |
4.15% | | Martin Currie Investment Management Ltd. | 2,025,666 |
2.85% | | Manning & Napier Advisors LLC | 1,435,270 |
2.02% | | Davis Selected Advisers LP | 1,250,546 |
1.76% | | The Leuthold Group LLC (Investment Management) | 1,223,360 |
1.72% |
|
| Company contact information |
|
Sinovac Biotech Ltd. No. 15 Zhi Tong Road Zhongguancun Science & Technology Changping District Beijing 102200 Phone : +86.10.5693.1800 Web : http://www.sinovacbio.com |
|
|
|
Wanted: More high-tech manufacturing space for a global vaccine push |
Sector Biopharmaceuticals
| | 1st jan. | Capitalization (M$) |
 |
 | SINOVAC BIOTECH LTD. | 0.00% | 640 |
| | | |
|
 | CSL LIMITED | -7.27% | 97 869 |
 | WUXI BIOLOGICS (CAYMAN) INC. | -6.57% | 56 633 |
 | SAMSUNG BIOLOGICS CO.,LTD. | -9.20% | 46 083 |
| BIOGEN INC. | 13.23% | 42 237 |
 | CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. | 17.96% | 41 868 |
| ALEXION PHARMACEUTICALS, INC. | -2.23% | 33 759 |
 | UCB | -2.41% | 19 864 |
| CELLTRION HEALTHCARE CO LTD | --.--% | 18 010 |
| SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD. | -12.29% | 16 465 |
 | GRIFOLS, S.A. | -12.81% | 15 627 |
| INNOVENT BIOLOGICS, INC. | -2.62% | 15 610 |
| CANSINO BIOLOGICS INC. | 109.07% | 15 528 |
| BIOMARIN PHARMACEUTICAL INC. | -11.70% | 14 842 |
| ZAI LAB LIMITED | 9.00% | 12 974 |
| SHANGHAI JUNSHI BIOSCIENCES CO., LTD. | 39.96% | 12 820 |
| BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED | 9.61% | 12 258 |
| WALVAX BIOTECHNOLOGY CO., LTD. | 18.80% | 11 155 |
| BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD. | -15.85% | 6 998 |
| TWIST BIOSCIENCE CORPORATION | -4.85% | 6 540 |
| ZHEJIANG WOLWO BIO-PHARMACEUTICAL CO., LTD. | -2.02% | 6 308 |
Connections : Sinovac Biotech Ltd. |
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
